AstraZeneca slashes US sales force by a quarter

Share this article:
AstraZeneca is slashing its US sales force by 24% as the company confronts a steep patent cliff.

The 1,150 job eliminations come on top of 8,000 US job cuts announced in 2010 and 400 more announced in October. The London-based company declined to say where the cuts will fall or how many will come through attrition, but said in a release that employees “will be given the option to self-identify to potentially leave the company.” AstraZeneca will take a $50 to $100 million hit in restructuring costs from the cuts, which will go towards the second four-year phase of a two-step downsizing exercise, this portion initiated in 2010 and aimed at wringing $1.9 billion in cost savings through 2014.

Two of the company's three $5 billion brands – Seroquel and Nexium – are set to lose patent exclusivity in the next two years, with $5.3 billion Seroquel going off-patent in 2012, along with $2.7 billion Symbicort, and $5 billion Nexium following in 2014. The third, Crestor, which brought in $5.6 billion in 2010, already faces competition from generic Lipitor, having recently failed to outperform the Pfizer drug on plaque progression in AstraZeneca's SATURN trial, and goes off-patent in 2016. A host of substantial AstraZeneca products have lost patent protection in the past few years, including Arimidex and Casodex, Pulmicort Respules and Toprol-XL, while the company has been hit by setbacks on several key pipeline products, including Brilinta, Onglyza, dapagliflozin and Iressa. Generic competition cost the firm $1.6 billion in 2010 alone.  

“We are building a leaner, more efficient US organization that will enable us to continue delivering against our mission of patient health while remaining a strong, sustainable business in the future,” said a company spokesman.

Like many of its large pharma peers, the company has also been on a share buyback tear, plunking down $2.1 billion on share repurchases in 2010, with $4 billion more planned for 2011.

In other AstraZeneca news, the firm announced its acquisition of a generics firm in China, where the company is already spending $200 million on an new manufacturing facility. The company saw more than $1 billion in sales in China last year, fueling emerging markets revenue growth of 16% while US revenues declined 7%.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...